Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
Recruiting
Early Phase 1
Interventional Study
Type 1 Diabetes Mellitus
Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY)
MODY2 Diabetes
Healthy Volunteer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 60
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 27 (estimated)
- Sponsor
- Vanderbilt University Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to understand the heart and blood sugar health benefits of using an adjunctive therapy to lower high insulin levels in people with type 1 diabetes. The investigators will also look at people with a specific type of diabetes called Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY) and those without diabetes to help interpret the results. The investigators will use a medica…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Age: 18-60 years BMI: 18-28 kg/m² Weight: ≥ 50 kg
T1DM Participants:
Duration of T1DM: 1-30 years HbA1c: 5.7-7.5% Insulin Therapy: Using automated insulin delivery
GCK-MODY Participants:
HbA1c: 5.7-7.5% Genetic Confirmation: Positive GCK sequencing
Control Participants:
Hb…
Contacts